To make matters more confusing, nine states (including California, Washington, and Colorado) let residents buy cannabis-based products with or without THC. Nearly two dozen other “medical marijuana states” allow the sale of cannabis, including capsules, tinctures, and other items containing CBD or THC, at licensed dispensaries to people whose doctors have certified that they have an approved condition (the list varies by state but includes chronic pain, PTSD, cancer, autism, Crohn’s disease, and multiple sclerosis). Sixteen more states legalized CBD for certain diseases. But because all these products are illegal according to the federal government, cannabis advocates are cautious. “By and large, the federal government is looking the other way,” says Paul Armentano, deputy director of the Washington, DC–based National Organization for the Reform of Marijuana Laws (NORML), but until federal laws are changed, “this administration or a future one could crack down on people who produce, manufacture, or use CBD, and the law would be on its side.”
Industrial hemp is marketed a fiber, as a seed, or as a dual-purpose crop. Although detailed market information for hemp ins not readily available, estimates from Vote Hemp show that the total retail value of hemp products in the U.S. in 2017 was $820 million. This includes food and body products, clothing, auto parts, building materials, and other products.
Based on world production of fibers in 1999, about 54.5% was synthetic (of which 60.3% was polyester), 42.9% was plant fiber (of which 78.5% was cotton), and 2.6% was wool (Karus 2000). In addition to cotton, flax is the only other significant plant fiber crop grown in temperate regions of the world (kenaf has received some enthusiastic backing in the southern US in recent years, but is most cheaply produced in India, Bangladesh, and China). Flax held 2.7% of the world plant fiber market in 1999, while hemp had only 0.3% (Karus 2000). Hemp fiber can potentially replace other biological fibers in many applications, but also, as noted below, can sometimes compete with minerals such as glass fiber and steel. As forests diminish, cultivation of annual plants as fiber sources is likely to increase. While crop residues like cereal straw will probably supply much of the need, specialty fiber plants such as hemp also have potential. The four conditions that will need to be met are (after Bolton 1995): (1) the material should be produced at a large enough scale; (2) the price should be low enough; (3) the fiber characteristics should be adequate for the end use; and (4) proven technology should be available for the processing of the new raw material. Of these criteria only point 3 is adequately met at this time for hemp in North America, but this is to be expected in a crop that has only begun to be cultivated after an absence of many years.

A USDA analysis of hemp, “Industrial hemp in the United States: Status and market potential,” was issued in 2000, and is available at This is anonymously-authored, therefore presumably represents a corporate or “official” evaluation. The conclusion was that “US markets for hemp fiber (specialty textiles, paper, and composites) and seed (in food or crushed for oil) are, and will likely remain, small, thin markets. Uncertainty about longrun demand for hemp products and the potential for oversupply discounts the prospects for hemp as an economically viable alternative crop for American farmers.” Noting the oversupply of hempseeds associated with Canada’s 12,000 ha in 1999, the report concluded that the long term demand for hemp products is uncertain, and predicts that the hemp market in the US will likely remain small and limited. With respect to textiles, the report noted the lack of a thriving textile flax (linen) US industry (despite lack of legal barriers), so that it would seem unlikely that hemp could achieve a better market status. With respect to hemp oil, the report noted that hemp oil in food markets is limited by its short shelf life, the fact that it can not be used for frying, and the lack of US Food and Drug Administration approval as GRAS (“generally recognized as safe”). Moreover, summarizing four state analyses of hemp production (McNulty 1995, Ehrensing 1998, Kraenzel et al. 1998, Thompson et al. 1998), profitability seemed doubtful.
Folks. This article has nothing whatsoever to do wiht legalization of marijuana. Why do you keep commenting on legalizing pot, medical or otherwise? This article is about hemp. TOTALLY different. As an agricultural product it is very adaptable, forgiving and has a multitude of uses. Please stay on topic and help to promote the valuable product of HEMP. South Carolina has made it legal to grow and the rest of the country would benefit from following suit. Again, this has absolutely nothing to do with Pot!!!!!
Following an 1836–1840 travel in North Africa and the Middle East, French physician Jacques-Joseph Moreau wrote on the psychological effects of cannabis use; Moreau was a member of Paris' Club des Hashischins (founded in 1844).[citation needed] In 1842, Irish physician William Brooke O'Shaughnessy, who had studied the drug while working as a medical officer in Bengal with the East India company, brought a quantity of cannabis with him on his return to Britain, provoking renewed interest in the West.[193] Examples of classic literature of the period featuring cannabis include Les paradis artificiels (1860) by Charles Baudelaire and The Hasheesh Eater (1857) by Fitz Hugh Ludlow.
Molecular analytical techniques developed in the late 20th century are being applied to questions of taxonomic classification. This has resulted in many reclassifications based on evolutionary systematics. Several studies of Random Amplified Polymorphic DNA (RAPD) and other types of genetic markers have been conducted on drug and fiber strains of Cannabis, primarily for plant breeding and forensic purposes.[73][74][24][75][76] Dutch Cannabis researcher E.P.M. de Meijer and coworkers described some of their RAPD studies as showing an "extremely high" degree of genetic polymorphism between and within populations, suggesting a high degree of potential variation for selection, even in heavily selected hemp cultivars.[36] They also commented that these analyses confirm the continuity of the Cannabis gene pool throughout the studied accessions, and provide further confirmation that the genus consists of a single species, although theirs was not a systematic study per se.
Prescription medicine (Schedule 4) for therapeutic use containing 2 per cent (2.0%) or less of other cannabinoids commonly found in cannabis (such as ∆9-THC). A schedule 4 drug under the SUSMP is Prescription Only Medicine, or Prescription Animal Remedy – Substances, the use or supply of which should be by or on the order of persons permitted by State or Territory legislation to prescribe and should be available from a pharmacist on prescription.[74]

Get Best CBD Oil